Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Targeted treatment for chronic lymphocytic leukemia.

Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A.

Onco Targets Ther. 2011;4:169-83. doi: 10.2147/OTT.S7173. Epub 2011 Nov 4.

2.

Promising therapies for the treatment of chronic lymphocytic leukemia.

Morabito F, Recchia AG, Vigna E, De Stefano L, Bossio S, Morabito L, Pellicanò M, Palummo A, Storino F, Caruso N, Gentile M.

Expert Opin Investig Drugs. 2015 Jun;24(6):795-807. doi: 10.1517/13543784.2015.1021920. Epub 2015 Mar 1. Review.

PMID:
25728009
3.

Signal transduction inhibitors in chronic lymphocytic leukemia.

Ma S, Rosen ST.

Curr Opin Oncol. 2011 Nov;23(6):601-8. doi: 10.1097/CCO.0b013e32834b8943. Review.

PMID:
21892084
4.

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.

Robak T, Lech-Maranda E, Robak P.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132. Review.

PMID:
20942624
5.

Novel agents for the treatment of chronic lymphocytic leukemia.

Abou-Nassar K, Brown JR.

Clin Adv Hematol Oncol. 2010 Dec;8(12):886-95. Review.

PMID:
21326166
6.

Biology and treatment of chronic lymphocytic leukemia.

Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ.

Hematology Am Soc Hematol Educ Program. 2003:153-75. Review.

PMID:
14633781
7.

Role of rituximab in first-line treatment of chronic lymphocytic leukemia.

Bryan J, Borthakur G.

Ther Clin Risk Manag. 2010 Dec 22;7:1-11. doi: 10.2147/TCRM.S5855.

8.

Chronic lymphocytic leukemia.

Byrd JC, Stilgenbauer S, Flinn IW.

Hematology Am Soc Hematol Educ Program. 2004:163-83. Review.

PMID:
15561682
9.

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC.

Blood. 2010 Nov 11;116(19):3705-14. doi: 10.1182/blood-2010-04-001230. Epub 2010 Jul 7. Review.

10.

Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?

Brown JR, Hallek MJ, Pagel JM.

Am Soc Clin Oncol Educ Book. 2016;35:e387-98. doi: 10.14694/EDBK_159018. Review.

11.

A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.

Owen C, Bence-Bruckler I, Chamakhi I, Toze C, Assaily W, Christofides A, Robinson S.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):303-13. doi: 10.1016/j.clml.2015.03.002. Epub 2015 Mar 26. Review.

PMID:
25937158
12.

Monoclonal antibodies in the treatment of chronic lymphoid leukemias.

Robak T.

Leuk Lymphoma. 2004 Feb;45(2):205-19. Review.

PMID:
15101704
13.

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV.

Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Review.

14.

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.

J Clin Oncol. 2010 Apr 1;28(10):1756-65. doi: 10.1200/JCO.2009.26.4556. Epub 2010 Mar 1.

PMID:
20194844
15.

Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.

Hillmen P.

Semin Oncol. 2004 Feb;31(1 Suppl 2):22-6. Review.

PMID:
15042531
16.

Chronic lymphocytic leukemia: current and emerging treatment approaches.

Kay NE, Rai KR, O'Brien S.

Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 22):1-10; quiz 11-2. Review.

PMID:
17143256
17.

Novel treatments for chronic lymphocytic leukemia and moving forward.

Brown JR, Porter DL, O'Brien SM.

Am Soc Clin Oncol Educ Book. 2014:e317-25. doi: 10.14694/EdBook_AM.2014.34.e317. Review.

18.

The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.

Main C, Pitt M, Moxham T, Stein K.

Health Technol Assess. 2010 Oct;14(Suppl. 2):27-32. doi: 10.3310/hta14suppl2/04. Review.

19.

Progress in CLL, chemotherapy, antibodies and transplantation.

Keating MJ.

Biomed Pharmacother. 2001 Nov;55(9-10):524-8.

PMID:
11769960
20.

Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.

Bogusz J, Majchrzak A, Mędra A, Cebula-Obrzut B, Robak T, Smolewski P.

Postepy Hig Med Dosw (Online). 2013 Mar 1;67:107-18.

Supplemental Content

Support Center